ImmunityBio announces $100M of financing transactions

ImmunityBio (IBRX) has secured $75M in non-dilutive financing under its existing Royalty Interest Purchase Agreement with Oberland Capital, increasing the total committed capital under the Agreement to $375M. The amended agreement maintains existing terms, with a modest increase in the royalty payback rate while maintaining the royalty cap. Simultaneous with the closing of the amendment to the RIPA, Nant Capital, an entity affiliated with our Executive Chairman, converted $25M principal amount with the issuance of 4.6M shares of the company’s common stock to Nant Capital and the reduction of debt under the $505M December 2024 Promissory Note